A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase 1 study during which patients with relapsed or refractory multiple myeloma (MM) or plasma cell leukemia (PCL) will receive investigational study drug ARRY-520 and bortezomib, with or without dexamethasone, with granulocyte-colony stimulating factor (G-CSF) support.

This study has 2 parts. In the first part, patients will receive increasing doses of study drug (2 dosing schedules will be evaluated) in combination with (1) bortezomib with G-CSF support or (2) bortezomib and dexamethasone with G-CSF support, in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Approximately 45 patients from the US will be enrolled in Part 1 (Active, not recruiting).

In the second part of this study, patients will receive the best dose(s) and schedule(s) of study drug, in combination with bortezomib ± dexamethasone + G-CSF, determined from the first part of the study and will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 42 patients from the US will be enrolled in Part 2 (Active, not recruiting).

Study Overview

• Status: Completed
• Conditions: Multiple Myeloma, Plasma Cell Leukemia
• Intervention / Treatment: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Drug: Dexamethasone, steroid; oral

• Study Type: Interventional
• Enrollment (Actual): 55
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Huntsville, Alabama, United States, 35805
      • Clearview Cancer Institute
  • Arizona
    • Tucson, Arizona, United States, 85715
      • Arizona Clinical Research Center, Inc.
  • California
    • Duarte, California, United States, 91010
      • City of Hope
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Emory University, Winship Cancer Institute
  • Maryland
    • Rockville, Maryland, United States, 20850
      • Associates in Oncology/Hematology
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • University of Michigan Comprehensive Cancer Center
    • Detroit, Michigan, United States, 48201
      • Karmanos Cancer Institute
  • New York
    • New York, New York, United States, 10029
      • Mount Sinai Medical Center
    • New York, New York, United States, 10016
      • NYU Cancer Center
  • South Carolina
    • Charleston, South Carolina, United States, 29414
      • Charleston Hematology Oncology Associates
  • Tennessee
    • Germantown, Tennessee, United States, 38138
      • The Jones Clinic
    • Nashville, Tennessee, United States, 37212
      • Vanderbilt-Ingram Cancer Center
  • Texas
    • Dallas, Texas, United States, 75246
      • Baylor Charles A. Sammons Cancer Center at Dallas

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria (Part 1 and Part 2):

• Confirmed relapsed or refractory MM (measurable disease) or PCL.
• Prior treatment regimens for Part 1: Patients should have received at least 2 prior treatment regimens. Prior treatment must have included at least one full cycle of a proteasome inhibitor (e.g., bortezomib or carfilzomib) and at least one full cycle of an IMiD (e.g., thalidomide, lenalidomide or pomalidomide).
• Prior treatment regimens for Part 2: Patients should have received 1 to 3 prior treatment regimens. Prior treatment could have included bortezomib only if the disease was not refractory to treatment with bortezomib (refractory defined as documented progression on therapy or within 60 days of completing treatment with bortezomib).
• The disease should have progressed per IMWG criteria during or after the last prior treatment regimen.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
• Adequate hematology laboratory values without transfusion support and without hematological growth factor support within 2 weeks of screening.
• Adequate liver and renal function.
• Additional criteria exist.

Key Exclusion Criteria (Part 1 and Part 2):

• Primary amyloidosis.
• Peripheral neuropathy ≥ Grade 2 or neuropathy with pain, regardless of grade.
• Concomitant malignancies or previous malignancies with less than a 3-year disease free interval at the time of enrollment (patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or Stage A low grade prostate cancer may enroll irrespective of the time of diagnosis).
• Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study drug.
• Treatment with an investigational medicinal product or device within 28 days prior to first dose of study drug.
• Cytotoxic therapy or monoclonal antibodies within 21 days prior to first dose of study drug.
• Radiotherapy within 21 days prior to first dose of study drug (if the radiation portal covered ≤ 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy).
• Major surgery within 14 days and minor surgery within 7 days prior to first dose of study drug.
• Corticosteroid doses > 10 mg/day of prednisone or equivalent within 14 days prior to first dose of study drug.
• Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or active hepatitis C.
• Additional criteria exist.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: ARRY-520 (Schedule 1) + bortezomib + G-CSF	Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.; Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Part 1: standard of care; Part 2: standard of care determined in Part 1.; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Part 1: standard of care; Part 2: standard of care.; Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Part 1: multiple dose, escalating; Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Part 1: standard of care; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Part 1: standard of care
EXPERIMENTAL: ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF	Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.; Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Part 1: standard of care; Part 2: standard of care determined in Part 1.; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Part 1: standard of care; Part 2: standard of care.; Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Part 1: multiple dose, escalating; Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Part 1: standard of care; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Part 1: standard of care; Drug: Dexamethasone, steroid; oral; Part 1: standard of care; Part 2: standard of care determined in Part 1.
EXPERIMENTAL: ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF	Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.; Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Part 1: standard of care; Part 2: standard of care determined in Part 1.; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Part 1: standard of care; Part 2: standard of care.; Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Part 1: multiple dose, escalating; Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Part 1: standard of care; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Part 1: standard of care; Drug: Dexamethasone, steroid; oral; Part 1: standard of care; Part 2: standard of care determined in Part 1.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Characterize the safety profile of the study drug in combination with bortezomib ± dexamethasone + G-CSF in terms of adverse events, clinical laboratory tests and electrocardiograms.	Part 1
Establish the maximum tolerated dose (MTD) of the study drug in combination with bortezomib ± dexamethasone + G-CSF.	Part 1
Assess the efficacy of study drug in combination with bortezomib ± dexamethasone + G-CSF in terms of best overall response	Part 2

Secondary Outcome Measures

Outcome Measure	Time Frame
Assess the efficacy of study drug in combination with bortezomib ± dexamethasone + G-CSF in terms of duration of response, time to progression, treatment-free interval and time to next treatment.	Part 1 and Part 2
Characterize the safety profile of the study drug in combination with bortezomib ± dexamethasone + G-CSF in terms of adverse events, clinical laboratory tests and electrocardiograms.	Part 2
Assess the pharmacokinetic (PK) drug interactions between ARRY-520 and bortezomib in terms of plasma concentration-time profiles.	Part 2

Collaborators and Investigators

• Sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer

Study record dates

Study Major Dates

• Study Start: December 1, 2010
• Primary Completion (ACTUAL): March 1, 2016

Study Registration Dates

• First Submitted: November 24, 2010
• First Submitted That Met QC Criteria: November 24, 2010
• First Posted (ESTIMATE): November 25, 2010

Study Record Updates

• Last Update Posted (ACTUAL): September 30, 2020
• Last Update Submitted That Met QC Criteria: September 28, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Keywords: relapsed multiple myeloma; plasma cell dyscrasia; plasmacytoma; kinesin spindle protein; anti-mitotic
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Immunoproliferative Disorders; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Leukemia; Multiple Myeloma; Neoplasms, Plasma Cell; Leukemia, Plasma Cell; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Enzyme Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Immunologic Factors; Antimitotic Agents; Mitosis Modulators; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Protease Inhibitors; Adjuvants, Immunologic; Dexamethasone; Lenograstim; Bortezomib; Proteasome Inhibitors; Filanesib
• Other Study ID Numbers: ARRAY-520-111